Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

NCT04213898 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT04213898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04213898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer
Lead sponsor
Henan Cancer Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 31, 2020
Completion date
January 31, 2023
Enrollment
39 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

triple-negative breast cancer